drugset / Trial / NCT00174538

Codeine in Sickle Cell Disease

NCT00174538

Phase 1/2 Completed 60 enrolled PriCara, Unit of Ortho-McNeil, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The objective of this study is to determine if a subject's genetic make-up would affect the treatment response to codeine in subjects with sickle cell disease.

Timeline

Start
2005-03
Primary completion
Completion
2005-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Codeine Small molecule 30 mg Oral

Indications